老年胶质母细胞瘤：建立在流沙上的可靠结论？
Glioblastoma in elderly patients: solid conclusions built on shifting sand?
机构信息
Neurology Clinic & German Consortium for Translational Cancer Research (DKTK), Heidelberg University Medical Center & DKFZ, Heidelberg, Germany.
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
出版信息
Neuro Oncol. 2018 Jan 22;20(2):174-183. doi: 10.1093/neuonc/nox133.
Abstract
Management of glioblastoma in the elderly population is challenging. In the near future, more than half of patients with this tumor will be over the age of 65. Clinicians have been historically reluctant to treat such patients with the same intensity as younger patients. Due to upper age limits or poor accrual of elderly patients in clinical trials, randomized data for this patient population have been relatively sparse until recently. In this review, we will discuss the concept of an elderly patient population, describe evidence for molecular differences in glioblastoma of elderly versus young patients, evaluate recent first-line trials studying glioblastoma in elderly patients, and discuss best therapeutic practices including the value of molecular testing.
摘要
老年胶质母细胞瘤的治疗颇具挑战。在不久的将来，超过一半的此类肿瘤患者年龄将超过 65 岁。临床医生在治疗此类患者时，往往不像对待年轻患者那样积极。由于临床试验对老年患者的年龄上限或入组标准较为严格，直到最近，此类患者群体的随机数据才相对较少。在这篇综述中，我们将讨论老年患者群体的概念，描述老年患者与年轻患者胶质母细胞瘤的分子差异证据，评估最近研究老年胶质母细胞瘤的一线治疗试验，并讨论最佳治疗方法，包括分子检测的价值。
相似文献
1
Glioblastoma in elderly patients: solid conclusions built on shifting sand?老年胶质母细胞瘤：建立在流沙上的可靠结论？
Neuro Oncol. 2018 Jan 22;20(2):174-183. doi: 10.1093/neuonc/nox133.
2
Treatment options and outcomes for glioblastoma in the elderly patient.老年胶质母细胞瘤患者的治疗选择与预后
Clin Interv Aging. 2014 Feb 21;9:357-67. doi: 10.2147/CIA.S44259. eCollection 2014.
3
Evidence-Based Practice: Temozolomide Beyond Glioblastoma.循证实践：替莫唑胺在胶质母细胞瘤之外的应用。
Curr Oncol Rep. 2019 Mar 5;21(4):30. doi: 10.1007/s11912-019-0783-5.
4
Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.IDH 野生型胶质母细胞瘤患者经同步和维持替莫唑胺放化疗的分层临床疗效和生存分析
J Cancer Res Clin Oncol. 2021 Jan;147(1):253-262. doi: 10.1007/s00432-020-03334-3. Epub 2020 Aug 3.
5
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.异柠檬酸脱氢酶突变可预测继发性胶质母细胞瘤患者的生存期延长和对替莫唑胺的反应。
Cancer Sci. 2012 Feb;103(2):269-73. doi: 10.1111/j.1349-7006.2011.02134.x. Epub 2011 Nov 28.
6
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.哪些新诊断的老年胶质母细胞瘤患者能从放疗和替莫唑胺中获益？一项PERNO前瞻性研究。
J Neurooncol. 2016 May;128(1):157-162. doi: 10.1007/s11060-016-2093-1. Epub 2016 Mar 4.
7
Sex as a biological variable in response to temozolomide.性别作为对替莫唑胺反应的生物学变量。
Neuro Oncol. 2017 Jun 1;19(6):873-874. doi: 10.1093/neuonc/nox040.
8
Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05).老年人胶质母细胞瘤放疗的现状：韩国放射肿瘤学会（KROG 21-05）脑肿瘤委员会的一项调查研究。
Jpn J Clin Oncol. 2022 Aug 5;52(8):843-849. doi: 10.1093/jjco/hyac060.
9
[MGMT and temozolomide sensibility].[甲基鸟嘌呤-DNA甲基转移酶与替莫唑胺敏感性]
Bull Cancer. 2021 Dec;108(12):1075-1076. doi: 10.1016/j.bulcan.2021.08.011. Epub 2021 Nov 12.
10
Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.替莫唑胺联合放疗治疗老年胶质母细胞瘤患者：一项“真实世界”报告。
Radiat Oncol. 2017 Dec 6;12(1):197. doi: 10.1186/s13014-017-0929-2.
引用本文的文献
1
Survival Determinants in Glioblastoma: An Insight into Biopsy-Only Patient Outcomes.胶质母细胞瘤的生存决定因素：对仅接受活检患者预后的洞察。
Biomedicines. 2024 Oct 13;12(10):2327. doi: 10.3390/biomedicines12102327.
2
No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients.特罗凯治疗 MGMT 启动子未甲基化的胶质母细胞瘤无效：老年胶质母细胞瘤患者 CE.6 和北欧/NOA-08 试验的再分析。
Neuro Oncol. 2024 Oct 3;26(10):1867-1875. doi: 10.1093/neuonc/noae108.
3
Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 1. Brain and head and neck.大分割放疗的循证临床建议：疗效与安全性探索 - 第1部分。脑及头颈部
Radiat Oncol J. 2024 Mar;42(1):17-31. doi: 10.3857/roj.2023.00899. Epub 2024 Mar 14.
4
Glioblastoma Therapy: Past, Present and Future.胶质母细胞瘤治疗：过去、现在和未来。
Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529.
5
Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology.脑肿瘤患者的虚弱与术后结局：按肿瘤病因细分的系统评价。
J Neurooncol. 2023 Sep;164(2):299-308. doi: 10.1007/s11060-023-04416-1. Epub 2023 Aug 25.
6
Prognostic nomogram models for predicting survival probability in elderly glioblastoma patients.用于预测老年胶质母细胞瘤患者生存概率的预后列线图模型。
J Cancer Res Clin Oncol. 2023 Nov;149(15):14145-14157. doi: 10.1007/s00432-023-05232-w. Epub 2023 Aug 8.
7
Updates in IDH-Wildtype Glioblastoma.IDH 野生型胶质母细胞瘤的最新进展。
Neurotherapeutics. 2022 Oct;19(6):1705-1723. doi: 10.1007/s13311-022-01251-6. Epub 2022 May 31.
8
The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma.临床虚弱量表对高级别胶质瘤切除术后总生存的预测价值。
J Neurooncol. 2022 May;158(1):15-22. doi: 10.1007/s11060-022-04001-y. Epub 2022 Apr 25.
9
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.在 IDH 野生型胶质母细胞瘤中观察到的基于 DNA 甲基化的年龄加速与更好的预后相关，包括在老年患者中。
Acta Neuropathol Commun. 2022 Mar 24;10(1):39. doi: 10.1186/s40478-022-01344-5.
10
Surgical and oncological score to estimate the survival benefit of resection and chemoradiotherapy in elderly (≥70 years) glioblastoma patients: A preliminary analysis.评估老年（≥70岁）胶质母细胞瘤患者手术及放化疗生存获益的外科与肿瘤学评分：一项初步分析。
Neurooncol Adv. 2022 Jan 28;4(1):vdac007. doi: 10.1093/noajnl/vdac007. eCollection 2022 Jan-Dec.
本文引用的文献
1
Glioblastoma in the elderly: making sense of the evidence.老年胶质母细胞瘤：解读相关证据
Neurooncol Pract. 2016 Jun;3(2):77-86. doi: 10.1093/nop/npv027. Epub 2015 Sep 1.
2
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.贝伐珠单抗联合低分割放疗与单纯放疗治疗老年胶质母细胞瘤患者的随机、开放标签、II 期 ARTE 试验。
Ann Oncol. 2018 Jun 1;29(6):1423-1430. doi: 10.1093/annonc/mdy120.
3
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.欧洲神经肿瘤学会（EANO）成人星形细胞瘤和少突胶质细胞瘤诊断和治疗指南。
Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016/S1470-2045(17)30194-8. Epub 2017 May 5.
4
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.短程放疗联合替莫唑胺治疗老年胶质母细胞瘤患者。
N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977.
5
Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.复发性胶质母细胞瘤的大规模放射组学分析确定了一种用于分层抗血管生成治疗反应的影像预测指标。
Clin Cancer Res. 2016 Dec 1;22(23):5765-5771. doi: 10.1158/1078-0432.CCR-16-0702. Epub 2016 Oct 10.
6
Evaluation of the Cost of Comprehensive Outpatient Therapies in Patients with Malignant Brain Tumors.恶性脑肿瘤患者综合门诊治疗费用评估
Am J Phys Med Rehabil. 2017 May;96(5):341-346. doi: 10.1097/PHM.0000000000000624.
7
Frailty and post-operative outcomes in older surgical patients: a systematic review.老年外科患者的衰弱与术后结局：一项系统综述
BMC Geriatr. 2016 Aug 31;16(1):157. doi: 10.1186/s12877-016-0329-8.
8
Age alone is not a predictor for survival in glioblastoma.仅年龄并不能作为胶质母细胞瘤患者生存情况的预测指标。
J Neurooncol. 2016 Sep;129(3):479-485. doi: 10.1007/s11060-016-2194-x. Epub 2016 Jul 12.
9
Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.替莫唑胺时代老年胶质母细胞瘤患者的放化疗联合治疗：国家癌症数据库分析。
JAMA Neurol. 2016 Jul 1;73(7):821-8. doi: 10.1001/jamaneurol.2016.0839.
10
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.2016 年世界卫生组织中枢神经系统肿瘤分类：概述。
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
Zotero 插件